Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.
Conditions
Interventions
VX-561
Placebo
+1 more
Locations
14
United States
University of Southern California
Los Angeles, California, United States
Stanford Hospital
Palo Alto, California, United States
Children's National Health
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Rush University
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Start Date
December 1, 2016
Primary Completion Date
August 1, 2017
Completion Date
August 1, 2017
Last Updated
August 26, 2020
NCT02417740
NCT06616857
NCT07108153
NCT02740868
NCT07274631
NCT07303621
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions